ArticleCureus2025
Evaluating Bone Grafting Success in Maxillofacial Surgery Among Patients With Oral Mucosal Diseases: A Prospective Cohort Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn maxillofacial surgery, bone grafting plays a critical role in alveolar defect reconstruction and dental bone grafts. Oral mucosal diseases (OMDs), including oral lichen planus and mucous membrane pemphigoid, may impair the local epithelial integrity and immune reactions. The objective of this research was to compare six-month graft integration between immune-mediated OMDs and those without and evaluate wound healing complications, surgical site infections, and factors of graft failure (immunosuppressive therapy, glycemic control, and smoking). MATERIALS AND
methodsA total of 86 patients who underwent autogenous or alloplastic bone grafting at a tertiary care hospital were studied between June 2023 and December 2023 as part of a prospective cohort study, with outcomes assessed at six months. The participants were divided into two groups: those with clinically and histopathologically proven OMDs (n = 38) and those without mucosa pathology (n = 48). The chart reviews and standardized follow-up exams (six months) were used to gather data on graft integration, wound healing, infection rates, immunosuppressive therapy, glycemic control, and smoking status. All statistical analyses were performed using SPSS Statistics version 26.0 (IBM Corp. Released 2019. IBM SPSS Statistics for Windows, Version 26.0. Armonk, NY: IBM Corp.), and a significance level of p = 0.05 was applied.
resultsOMD patients showed significantly reduced graft success rates, 27 (71.1%) vs. 44 (91.6%), p = 0.018, and an elevated incidence of wound healing complications, 11 (28.9%) vs. 5 (10.4%), p = 0.031, compared to the control group. Strong associations were found between immunosuppressive therapy (OR: 4.87, CI: 1.39-17.1, p = 0.013) and poor glycemic control (OR: 3.24, CI: 1.11-9.52, p = 0.031), as well as graft failure in the OMD group, with smoking showing a non-significant trend.
conclusionsThe prevalence of underlying OMDs was found to be associated with reduced success of bone grafts; after adjustment, failure was primarily linked to the use of immunosuppressive therapy and poor glycemic control. Successful perioperative screening, optimized metabolic management, and immunosuppressive management contribute to better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.